Although PPARα agonists have been shown to reduce circulatory lipids, clinical trials on non‐alcoholic fatty liver disease (NAFLD) have not reported any improvement in hepatic steatosis (Bajaj et al, 2007; Fernandez‐Miranda et al, 2008). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.